cmi_logo.png
[Latest] Global 3D Cell Culture Market Size/Share Worth USD 4.6 Billion by 2033 at a 11.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 18, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Cell Culture Market Size, Trends and Insights By Product (Scaffolds Based 3d...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
April 15, 2024 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
23andMe_Logo_grey.png
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024 16:05 ET | 23andMe, Inc.
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting...
zealand_logo_RGB_01.png
Total number of shares and voting rights in Zealand Pharma at March 31, 2024
March 31, 2024 11:00 ET | Zealand Pharma
Company announcement – No. 21 / 2024 Total number of shares and voting rights in Zealand Pharma at March 31, 2024 Copenhagen, Denmark, March 31, 2024 – Zealand Pharma A/S (“Zealand”)...
Celcuity+Logo.jpg
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 16:01 ET | Celcuity Inc.
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data...
zealand_logo_RGB_01.png
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
March 26, 2024 17:05 ET | Zealand Pharma
Company announcement – No. 20 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
zealand_logo_RGB_01.png
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
March 26, 2024 17:00 ET | Zealand Pharma
Company announcement – No. 19 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 26, 2024 – Zealand Pharma A/S...
zealand_logo_RGB_01.png
Zealand Pharma major shareholder announcement: Van Herk Investments
March 21, 2024 13:00 ET | Zealand Pharma
Company announcement – No. 18 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 21 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL)...
zealand_logo_RGB_01.png
Zealand Pharma's Annual General Meeting 2024
March 20, 2024 12:39 ET | Zealand Pharma
Company announcement – No. 17 / 2024 Zealand Pharma's Annual General Meeting 2024 Copenhagen, March 20, 2024 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held...
zealand_logo_RGB_01.png
Zealand Pharma major shareholder announcement: Polar Capital
March 19, 2024 12:05 ET | Zealand Pharma
Company announcement – No. 16 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 19 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no....